<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00023868</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068871</org_study_id>
    <secondary_id>ACRIN-6655</secondary_id>
    <secondary_id>U01CA079778</secondary_id>
    <secondary_id>U01CA080098</secondary_id>
    <nct_id>NCT00023868</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)</brief_title>
  <official_title>A Randomized Phase I/III Study Of Systematic Chemotherapy With Or Without Hepatic Chemoembolization For Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American College of Radiology Imaging Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>American College of Radiology Imaging Network</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work&#xD;
      in different ways to stop the growth of cancer cells, either by killing the cells or by&#xD;
      stopping the cells from dividing. Chemoembolization kills tumor cells by blocking the blood&#xD;
      flow to the tumor and keeping chemotherapy drugs near the tumor. It is not yet known if&#xD;
      chemoembolization is more effective than standard chemotherapy in treating metastatic cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial and randomized phase III trial is studying the effectiveness of&#xD;
      chemoembolization in treating patients who have colorectal cancer metastatic to the liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the survival of patients with liver-dominant metastatic colorectal&#xD;
           adenocarcinoma treated with irinotecan, fluorouracil, and leucovorin calcium with or&#xD;
           without hepatic chemoembolization.&#xD;
&#xD;
        -  Compare response in the liver, time to hepatic tumor progression, and time to&#xD;
           extrahepatic tumor progression in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the possible treatment differences with respect to morbidity, toxic effects of&#xD;
           chemoembolization, toxic effects of chemotherapy, and death from cancer-related&#xD;
           complications in these patients.&#xD;
&#xD;
      OUTLINE: This is a phase I dose-escalation study followed by a phase III randomized,&#xD;
      multicenter study. (Phase I closed as of 10/14/02.)&#xD;
&#xD;
        -  Phase I: Patients in phase I are sequentially enrolled to 1 of 3 treatment regimens.&#xD;
           (Phase I closed as of 10/14/02.)&#xD;
&#xD;
             -  Regimen A: Patients receive irinotecan IV over 60-90 minutes, leucovorin calcium&#xD;
                IV, and fluorouracil IV over 10 minutes on days 1, 8, 15, and 22. Patients undergo&#xD;
                hepatic embolization with embolic suspension only on day 36.&#xD;
&#xD;
             -  Regimen B: Patients receive chemotherapy as in regimen A. Patients undergo hepatic&#xD;
                chemoembolization with lower-dose cisplatin, doxorubicin, and mitomycin on day 36.&#xD;
&#xD;
             -  Regimen C: Patients receive chemotherapy as in regimen A. Patients undergo hepatic&#xD;
                chemoembolization with higher-dose cisplatin, doxorubicin, and mitomycin on day 36.&#xD;
&#xD;
      After 1 week of rest, patients in all regimens receive a second 4-week course of systemic&#xD;
      chemotherapy.&#xD;
&#xD;
      Cohorts of 3-10 patients are sequentially enrolled until the maximum tolerated dose (MTD) of&#xD;
      chemotherapy and chemoembolization is determined. The MTD is defined as the dose preceding&#xD;
      that at which at least 4 of 10 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase III: Patients are stratified according to liver volume involvement (less than 25%&#xD;
           vs 25-50% vs more than 50% to less than 75%) and participating center. Patients are&#xD;
           randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive irinotecan IV over 60-90 minutes, leucovorin calcium IV,&#xD;
                and fluorouracil IV over 10 minutes on days 1, 8, 15, and 22. Courses repeat every&#xD;
                6 weeks in the absence of disease progression.&#xD;
&#xD;
             -  Arm II: Patients receive chemotherapy as in arm I. Patients undergo hepatic&#xD;
                chemoembolization with cisplatin, doxorubicin, and mitomycin on day 36.&#xD;
                Chemotherapy repeats every 6 weeks in the absence of disease progression.&#xD;
                Chemoembolization may repeat every 6 weeks for 2-4 courses as necessary.&#xD;
&#xD;
      Patients in phase III are followed every 3 months for 2 years, every 6 months for 3 years,&#xD;
      and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 9-18 patients will be accrued for phase I of this study. (Phase&#xD;
      I closed to accrual as of 10/14/02.) Approximately 315 patients will be accrued for phase III&#xD;
      of this study within 2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    redesign&#xD;
  </why_stopped>
  <start_date type="Actual">November 1, 2001</start_date>
  <completion_date type="Actual">September 25, 2002</completion_date>
  <primary_completion_date type="Actual">September 25, 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic colorectal adenocarcinoma&#xD;
&#xD;
               -  Measurable metastasis to liver at least 1.0 cm&#xD;
&#xD;
                    -  Less than 75% of total liver volume&#xD;
&#xD;
               -  Known extrahepatic disease limited to lymph nodes and less than 2 cm&#xD;
&#xD;
               -  No ascites&#xD;
&#xD;
          -  Ineligible for surgery&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute granulocyte count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 90,000/mm^3&#xD;
&#xD;
          -  No bleeding diathesis not correctable by standard therapy&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Ineligible if all of the following criteria are concurrently present:&#xD;
&#xD;
               -  High risk of hepatic failure (more than 50% liver involvement by tumor)&#xD;
&#xD;
               -  Bilirubin greater than 2.0 mg/dL&#xD;
&#xD;
               -  SGOT greater than 100 U/L&#xD;
&#xD;
               -  Lactate dehydrogenase greater than 425 U/L&#xD;
&#xD;
          -  No hepatic encephalopathy&#xD;
&#xD;
          -  No portal vein occlusion without hepatopedal collateral flow demonstrated by&#xD;
             angiography&#xD;
&#xD;
          -  No portal hypertension with hepatofugal flow&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No evidence of congestive heart failure&#xD;
&#xD;
          -  No severe peripheral vascular disease that would preclude catheterization&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No severe allergy or intolerance to contrast media, narcotics, sedatives, or atropine&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No more than 1 prior adjuvant immunotherapy regimen for colon cancer&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 6 months since prior adjuvant chemotherapy and recovered&#xD;
&#xD;
          -  No more than 1 prior adjuvant chemotherapy regimen for colon cancer&#xD;
&#xD;
          -  No prior hepatic arterial infusion chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 1 month since prior radiotherapy&#xD;
&#xD;
          -  No prior hepatic radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 1 month since prior surgery&#xD;
&#xD;
          -  Prior surgical resection or ablation of liver metastases allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael C. Soulen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York - Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>June 16, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2003</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

